-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: drug development
Breast Cancer and Biotechnology: Bigger Than Pink
By David Welch, President/Senior Producer at M2 MultiMedia It had been five years since I produced Biotechnology: Knowledge Serving Life, a video that featured breast cancer patient Lori Lober and her then five year anniversary of being cancer free. Diagnosed with Stage IV metastatic breast cancer in 2000 Lori had been admitted to an advanced clinical trial for a promising new biologic. Today, Lori credits her treatment for helping to save her life. During the Read More >
Repositioning Drugs for Parkinson’s Disease
Last month, The Michael J. Fox Foundation (MJFF) announced the launch of its Repositioning Drugs for PD 2012 program. The program follows a successful 2011 during which the Foundation funded nine awards totaling $3.4 million repositioning existing drugs that could benefit Parkinson’s disease patients. The program seeks projects that will test drugs that are either already FDA-approved or that have been proven safe in a clinical trial for a certain indication, to determine whether the Read More >
Beyond the ABCs of ADCs
The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >
Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice
Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >
Perspective on Market Valuation for Biotech Drug Developers
Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >
